Technology Innovation Institute’s Secure Systems Research Centre in Abu Dhabi Announces Launch of First Motion Capture Facility Outside United States
8.9.2021 15:29:00 EEST | Business Wire | Press release
Technology Innovation Institute (TII), the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), today announced that its Secure Systems Research Centre (SSRC) is pioneering a first-in-the-region Motion Capture (MOCAP) facility. Outside of the United States, SSRC’s unique MOCAP facility at its Masdar City premises, will enable the testing of Unmanned Aerial Systems (UAS) or drones in an augmented reality (AR) or mixed reality environment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210908005700/en/
Dr Shreekant (Ticky) Thakkar, Chief Researcher, Secure Systems Research Centre, Technology Innovation Institute (Photo: AETOSWire)
The MOCAP facility will allow SSRC to simulate flying through the city of Abu Dhabi and enable high-precision ground truth to conduct sophisticated experiments as well as virtual, augmented and mixed reality testing. The ability to simulate virtual camera images and sensors facilitates testing in environments that are too large, too dangerous, or too time consuming to construct in reality.
The high-quality motion capture system proposed for Abu Dhabi will be able to conduct passive or active tracking and enhance the communication, navigation, command, and control capabilities achieved to date. SSRC is shaping this facility in line with its ongoing collaboration with US-based Purdue University that holds the distinction for the largest indoor motion capture facility in the world.
Speaking on the breakthrough facility that will allow the modelling and operation of a cloud-based secure autonomous system of drones - as opposed to just autonomous drones - in this environment, Dr Shreekant (Ticky) Thakkar, Chief Researcher, SSRC, said: “This is a start – an ambitious one – and we are confident we will be able to arrive at technologies that could limit malicious cyber-attacks as our reliance on drones continues to increase every day. They are integral to life today – from delivering valuable organs at a hospital to conducting surveillance of high-security zones, or dispersing seeds over a field or even completing grocery deliveries.
“This unique testing facility will be leveraged by various lab groups and allow us to conduct experiments on a broad range of Unmanned Aerial Systems of various sizes while the state-of-the-art high-resolution cameras track small objects in the surrounding environment. Our aim at SSRC is to develop breakthrough security solutions to safeguard systems that may be vulnerable, such as unsecure drone systems which may pose various threats to organisational or even individual privacy and safety. Therefore, it’s essential to make drone platforms more resilient and secure.”
On the construction of the new facility, James Goppert, Managing Director of the Purdue UAS Research and Test Facility said: “Autonomous drones are already playing a key part in package delivery and infrastructure inspection. As smart cities evolve, it will be critical to ensure the safe operation of drones in an urban setting. This facility is particularly suited to the task of bringing algorithms for the security of drones from simulation to real world application by allowing a gradual transition of scenario elements from pure simulation, to virtual, to real-world.”
The testing facility will be used by both the Secure Systems Research Centre and TII’s Autonomous Robotics Research Centre to carry out experiments on a range of vehicles. As a shared space, the Motion Capture facility can accommodate micro UAS weighing less than 10 g to large UAS that are as heavy as 1,000 kg and factor in different types of UAS from multirotor to helicopters to vertical takeoff and landing vehicles (VTOLs) to fixed wing craft.
For information on Technology Innovation Institute, visit www.tii.ae
For information on Secure Systems Research Centre, visit https://securesystems.tii.ae/
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210908005700/en/
Contact information
Technology Innovation Institute
Hanz Valbuena
comms@atrc.ae
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
